⚠ Evidence note: An aging clock is a statistical model, not a measurement of aging itself; predictive validity varies widely between clocks and populations.
Clonal Hematopoiesis (CHIP) as Aging Marker
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-14 — Beyond Hematopoiesis: How Immune Are Hematopoietic Stem Cells?: [mechanism-plausible] Review synthesizes how inflammatory sensing and lasting epigenetic reprogramming in hematopoietic stem cells may connect chronic activation to replicative stress, myeloid bias, and selection of CHIP clones, without establishing new outcome-prediction validity or showing that reversing these changes improves health. [mechanism-plausible] (novelty: 3)
- 2026-10-10 — Bone marrow adipose tissue in cardiometabolic disease: marrow niche remodeling, inflammatory hematopoiesis, and vascular pathology.: cross-connection with bmat-marrow-imaging: Review links BMAT expansion to inflammatory hematopoiesis in the marrow niche, a shared substrate with CHIP-driven aging pathology. (novelty: 3)
- 2026-09-28 — Deep Learning Predicts Hematopoietic Stem Cell Aging From 3D Chromatin Images: cross-connection with chromatin-3d-imaging-age: HSC-aging imaging readouts and CHIP-based somatic-mosaicism markers both sample the same stem-cell compartment; cross-validation could test whether chromatin-architecture age tracks CHIP burden independently of DNAm clocks. (novelty: 3)
- 2026-07-16 — Clonal haematopoiesis of indeterminate potential and epigenetic age acceleration: Systematic review and meta-analysis.: Systematic review and meta-analysis (~7,000 midlife-to-older adults) found CHIP carriers show elevated epigenetic age acceleration on Horvath, Hannum, PhenoAge, and GrimAge, with larger and more consistent effects for TET2-mutated clones and larger clone sizes — first pooled quantification of CHIP–epigenetic-age links with driver-gene and clone-size stratification, observational. [human-observational] (novelty: 3)
- 2026-08-12 — Clonal hematopoiesis of undetermined potential as an emerging determinant of inflammageing, and age-related diseases: Potential role as biomarker and target.: Narrative review framing CHIP as an emerging determinant of inflammaging and age-related disease risk, with potential dual role as biomarker and pharmacological prevention target; notes risk models, screening pathways, and clinical translation remain underdeveloped. [expert-opinion] (novelty: 3)
- 2026-09-16 — Retrotransposable element derepression distinguishes DNMT3A-mutant from TET2-mutant clonal haematopoiesis.: Observational multi-omic comparison found high-VAF DNMT3A-mutant CHIP shows retrotransposable-element (LINE/LTR) derepression linked to TNF-α/NF-κB, interferon, and senescence inflammatory signatures, whereas TET2-mutant clones lack RTE-driven inflammation and instead enrich OXPHOS, ROS, and mTORC1 pathways — a mutation-specific mechanistic split within CHIP. [human-observational] (novelty: 3)
Open questions
Related
Contributing findings
Beyond Hematopoiesis: How Immune Are Hematopoietic Stem Cells?
14-nov-2026
novelty 3
per-area 3
strengthens
Epigenetic regulation of the complement system in age-related chronic inflammation: mechanisms and therapeutic prospects.
12-nov-2026
novelty 2
per-area 2
mentions
Retrotransposable element derepression distinguishes DNMT3A-mutant from TET2-mutant clonal haematopoiesis.
16-sep-2026
novelty 3
per-area 3
strengthens
CHIP in Health and Disease
21-aug-2026
novelty 2
per-area 2
strengthens
Clonal hematopoiesis of undetermined potential as an emerging determinant of inflammageing, and age-related diseases: Potential role as biomarker and target.
12-aug-2026
novelty 3
per-area 3
strengthens
Clonal haematopoiesis of indeterminate potential and epigenetic age acceleration: Systematic review and meta-analysis.
16-jul-2026
novelty 3
per-area 3
strengthens
Aging, Geriatric Syndromes and Clonal Hematopoiesis
13-jul-2026
novelty 2
per-area 2
mentions